# US 2019/0169627 A1 · Algal lipid productivity via genetic modification of a signaling protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169627 A1
- Document ID: US20190169627A1
- Status: Published application
- Kind: A1
- Application number: 16/209,655
- Filed: 2018-12-04
- Published: 2019-06-06
- Earliest claimed: 2017-12-05
- Assignees: Synthetic Genomics, Inc.
- Applicants: Synthetic Genomics, Inc.
- Inventors: Imad Ajjawi
- Web page: https://patentgrep.com/patent/US20190169627A1

## CPC

- C12P 7/64: Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C07K 14/405: from algae
- C12N 15/8247: {involving modified lipid metabolism, e.g. seed oil composition}
- C12N 15/8216: {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides mutant microorganisms having attenuated expression of a gene encoding a polypeptide that includes a GAF domain wherein the mutant microorganisms have higher lipid productivity and/or exhibit increased partitioning of carbon to lipid as compared to wild-type microorganisms from which they are derived. Also provided are methods of producing lipids using the mutant microorganisms, guide RNAs, and nucleic acid constructs used for producing mutant microorganisms.

## Claims

### Claim 1

A mutant microorganism having attenuated expression of a gene encoding a polypeptide that comprises a GAF domain, wherein the mutant microorganism:
a) produces at least about 25% more lipid than a control microorganism; and/or
b) exhibits increased partitioning of carbon to lipid with respect to the control microorganism;
when the mutant microorganism and control microorganism are cultured under identical conditions.

### Claim 2 (depends on 1)

The mutant microorganism of claim 1, wherein the GAF domain is a GAF2 domain.

### Claim 3 (depends on 2)

The mutant microorganism of claim 2, wherein the GAF2 domain has at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the amino acid sequence set forth in SEQ ID NO:1.

### Claim 4 (depends on 2)

The mutant microorganism of claim 2, wherein the GAF2 domain comprises the amino acid sequence set forth in SEQ ID NO:1, or a conservative variant thereof.

### Claim 5 (depends on 1)

The mutant microorganism of claim 1, wherein the polypeptide comprises an amino acid sequence having at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the amino acid sequence set forth in SEQ ID NO:2.

### Claim 6 (depends on 1)

The mutant microorganism of claim 1, wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2, or a conservative variant thereof.

### Claim 7 (depends on 1)

The mutant microorganism of claim 1, wherein the mutant microorganism comprises one or more mutations to or affecting the expression of a gene in the Naga_100020g79 locus or a syntenic locus in a heterokont or algal species.

### Claim 8 (depends on 7)

The mutant microorganism of claim 7, wherein the mutant microorganism comprises a mutation to, or a mutation affecting the expression of, a gene comprising an open reading frame having at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO: 3.

### Claim 9 (depends on 7)

A mutant microorganism of claim 7, wherein said one or more mutations are present in or affect expression of: a nucleic acid encoding a polypeptide comprising an amino acid sequence having at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO:1 or SEQ ID NO:2; and/or comprising an open reading frame that comprises a nucleotide sequence having at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO:3 or SEQ ID NO:4.

### Claim 10 (depends on 7)

The mutant microorganism of claim 7, wherein the one or more mutations are in the GAF domain of the gene in the Naga_100020g79 locus.

### Claim 11 (depends on 1)

A mutant microorganism of claim 1, wherein the control microorganism is a wild type microorganism.

### Claim 12 (depends on 1)

A mutant microorganism of claim 1, wherein the mutant microorganism produces at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, at least about 200%, at least about 210%, at least about 220%, at least about 230%, at least about 240%, or at least about 250% more fatty acid methyl ester-derivatizable lipids (FAME lipids) than a control microorganism.

### Claim 13 (depends on 12)

The mutant microorganism of claim 12, wherein the mutant microorganism produces at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, at least about 200%, at least about 210%, at least about 220%, at least about 230%, at least about 240%, or at least about 250% more fatty acid methyl ester-derivatizable lipids (FAME lipids) than a control microorganism when cultured in a culture medium comprising nitrate as the sole nitrogen source.

### Claim 14 (depends on 12)

The mutant microorganism of claim 12, wherein the mutant microorganism is an alga and produces at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, at least about 200%, at least about 210%, at least about 220%, at least about 230%, at least about 240%, or at least about 250% more FAME lipids than a control alga when cultured under photoautotrophic conditions.

### Claim 15 (depends on 12)

The mutant microorganism of claim 12, wherein the microorganism produces at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 110%, or at least about 120% more storage lipids than the control microorganism.

### Claim 16 (depends on 15)

The mutant microorganism of claim 15, wherein the storage lipids are triacylglycerols (TAGs).

### Claim 17 (depends on 1)

The mutant microorganism of claim 1, wherein the mutant microorganism exhibits a FAME/TOC ratio at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 120%, at least about 140%, at least about 160%, at least about 180%, at least about 200%, at least about 220%, at least about 240%, at least about 260%, at least about 280%, at least about 300%, at least about 320%, at least about 340%, at least about 360%, at least about 380%, or at least about 400% higher than the FAME/TOC ratio of the control microorganism.

### Claim 18 (depends on 17)

The mutant microorganism according to claim 17, wherein the mutant microorganism exhibits a FAME/TOC ratio of at least about 0.35.

### Claim 19 (depends on 1)

The mutant microorganism of claim 1, wherein lipid productivity is determined in a batch, semicontinuous, or continuous productivity assay.

### Claim 20 (depends on 1)

The mutant microorganism of claim 1, wherein said identical conditions comprise culturing said mutant and control microorganisms in a medium comprising less than 2 mM ammonium.

### Claim 21 (depends on 20)

The mutant microorganism according to claim 20, wherein said identical conditions comprise culturing said mutant and control microorganisms in a medium comprising nitrate as substantially the sole nitrogen source.

### Claim 22 (depends on 1)

The mutant microorganism of claim 1, wherein said identical conditions comprise culturing said mutant and control microorganisms in a medium that is nutrient replete with respect to the control microorganism.

### Claim 23 (depends on 1)

A mutant microorganism of claim 1, wherein the mutant microorganism is a classically-derived mutant or a genetically engineered mutant.

### Claim 24 (depends on 23)

The mutant microorganism of claim 23, wherein the mutant microorganism has a mutation in the gene encoding a polypeptide that comprises a GAF domain, or a gene affecting the expression thereof, that results in a decrease of expression of said gene encoding a polypeptide that includes a GAF domain compared to expression of the gene in a control microorganism.

### Claim 25 (depends on 23)

The mutant microorganism of claim 23, wherein the mutation is a knockdown mutation.

### Claim 26 (depends on 25)

The mutant microorganism according to claim 25, wherein the knockdown mutation is generated using a Cas/CRISPR system.

### Claim 27 (depends on 23)

The mutant microorganism of claim 23, wherein the mutant microorganism comprises an RNAi construct, a ribozyme construct, or an antisense construct that targets the gene encoding the polypeptide having a GAF domain, or a gene affecting the expression thereof.

### Claim 28 (depends on 24)

The mutant microorganism of claim 24, wherein the mutant microorganism has a knockout mutation in the gene encoding a polypeptide that comprises a GAF domain, or a gene affecting the expression thereof.

### Claim 29 (depends on 28)

The mutant microorganism according to claim 28, wherein the knockout mutation is produced by site directed homologous recombination.

### Claim 30 (depends on 28)

The mutant microorganism of claim 28, wherein the knockout mutation disrupts the gene by partial or total deletion, truncation, frameshifting, or insertional mutation.

### Claim 31 (depends on 28)

The mutant microorganism of claim 28, wherein the knockout mutation is generated using meganuclease, zinc finger nuclease, a Transcription Activator-Like Effector Nuclease (TALEN) system, and/or a Cas/CRISPR system.

### Claim 32 (depends on 26)

The mutant microorganism of claim 26, wherein the mutant microorganism comprises a Cas/CRISPR-mediated insertion into the gene.

### Claim 33 (depends on 1)

The mutant microorganism of claim 1, wherein the mutant microorganism comprises at least one additional genetic modification that confers herbicide resistance, toxin resistance, enhanced growth properties, enhanced photosynthetic efficiency, enhanced lipid production or accumulation, and/or production of particular lipids.

### Claim 34 (depends on 1)

The mutant microorganism of claim 1, wherein the mutant microorganism is an algal or heterokont species.

### Claim 35 (depends on 34)

The mutant microorganism according to claim 34, wherein the mutant microorganism is an algal species selected from the group consisting of Achnanthes, Amphiprora, Amphora, Ankistrodesmus, Asteromonas, Boekelovia, Bolidomonas, Borodinella, Botrydium, Botryococcus, Bracteococcus, Chaetoceros, Carteria, Chlamydomonas, Chlorococcum, Chlorogonium, Chlorella, Chroomonas, Chrysosphaera, Cricosphaera, Crypthecodinium, Cryptomonas, Cyclotella, Desmodesmus, Dunaliella, Elipsoidon, Emiliania, Eremosphaera, Ernodesmius, Euglena, Eustigmatos, Franceia, Fragilaria, Fragilaropsis, Gloeothamnion, Haematococcus, Hantzschia, Heterosigma, Hymenomonas, Isochrysis, Lepocinclis, Micractinium, Monodus, Monoraphidium, Nannochloris, Nannochloropsis, Navicula, Neochloris, Nephrochloris, Nephroselmis, Nitzschia, Ochromonas, Oedogonium, Oocystis, Ostreococcus, Parachlorella, Parietochloris, Pascheria, Pavlova, Pelagomonas, Phceodactylum, Phagus, Picochlorum, Platymonas, Pleurochrysis, Pleurococcus, Prototheca, Pseudochlorella, Pseudoneochloris, Pseudostaurastrum, Pyramimonas, Pyrobotrys, Scenedesmus, Schizochlamydella, Skeletonema, Spyrogyra, Stichococcus, Tetrachlorella, Tetraselmis, Thalassiosira, Tribonema, Vaucheria, Viridiella, Vischeria, and Volvox.

### Claim 36 (depends on 34)

The mutant microorganism according to claim 34, wherein the mutant microorganism is a heterokont selected from the group consisting of bacillariophytes, eustigmatophytes, xanthophytes, phaeophytes, chrysophytes, or raphidophytes.

### Claim 37 (depends on 34)

The mutant microorganism according to claim 34, wherein the mutant microorganism is a heterokont selected from the group consisting of a Labyrinthulomycite species of Labryinthula, Labryinthuloides, Thraustochytrium, Schizochytrium, Aplanochytrium, Aurantiochytrium, Oblongichytrium, Japonochytrium, Diplophrys, or Ulkenia.

### Claim 38 (depends on 34)

The mutant microorganism according to claim 34, wherein the mutant microrganism is a heterokont alga.

### Claim 39 (depends on 38)

The mutant microorganism according to claim 38, wherein the mutant microrganism is a Eustigmatophyte.

### Claim 40 (depends on 39)

The mutant microorganism according to claim 39, wherein the mutant microrganism is a species of a genus selected from the group consisting of Chloridella, Chlorobptrys, Ellipsoidion, Eustigmatos, Goniochloris, Monodopsis, Monodus, Nannochloropsis, Pseudocharaciopsis, Pseudostaruastrum, Pseudotetraedriella, and Vischeria.

### Claim 41 (depends on 38)

The mutant microorganism according to claim 38, wherein the mutant microrganism is a Bacilliarophyte.

### Claim 42 (depends on 41)

The mutant microorganism according to claim 41, wherein the mutant microrganism is a species of a genus selected from the group consisting of Amphora, Chaetoceros, Cyclotella, Fragilaria, Fragilaropsis, Hantzschia, Navicula, Nitzschia, Phceodactylum, and Thalassiosira.

### Claim 43 (depends on 1)

A method of producing lipid, comprising culturing a mutant microorganism according to claim 1 in a culture medium to produce lipid.

### Claim 44 (depends on 43)

The method of claim 43, further comprising isolating lipid from the microorganism, the culture medium, or both.

### Claim 45 (depends on 43)

The method of claim 43, wherein the microorganism is cultured using batch, continuous, or semi-continuous culture conditions.

### Claim 46 (depends on 43)

The method of claim 43, wherein the microorganism is an alga and the culturing is under photoautotrophic conditions.

### Claim 47 (depends on 43)

The method of claim 43, wherein the microorganism is Labyrinthulomycite and the culturing is under heterotrophic conditions.

### Claim 48 (depends on 43)

The method of claim 43, wherein the microorganism is cultured in a photobioreactor or fermenter.

### Claim 49 (depends on 43)

The method of claim 43, wherein the microorganism is grown in a pond, canal, sea-based growth container, trench, raceway, or channel.

### Claim 50

A guide RNA of a CRISPR system, wherein the guide RNA comprises a sequence corresponding to SEQ ID NO:4.

### Claim 51 (depends on 50)

The guide RNA according to claim 50, wherein the guide RNA is a chimeric guide.

### Claim 52 (depends on 50)

The guide RNA according to claim 50, wherein the guide RNA does not include a tracr sequence.

### Claim 53

A nucleic acid construct for homologous recombination comprising a nucleotide sequence from or adjacent to a naturally-occurring algal gene encoding a polypeptide having an amino acid sequence with at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO:1 or SEQ ID NO:2; a gene localized to the Naga_100020g79 locus; and/or a gene that comprises an ORF comprising a sequence having at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO:3 and/or SEQ ID NO:4.

### Claim 54

A nucleic acid construct for expression of an antisense RNA, shRNA, microRNA, or ribozyme comprising a nucleotide sequence complementary to at least a portion of a naturally-occurring gene encoding a polypeptide having an amino acid sequence with at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO:1 or SEQ ID NO:2; a gene localized to the Naga_100020g79 locus; and/or a gene that comprises an ORF comprising a sequence having at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO:3 and/or SEQ ID NO:4.

### Claim 55

A nucleic acid molecule encoding a guide RNA of a CRISPR system, wherein the guide RNA comprises at least a portion of a naturally-occurring algal gene encoding a polypeptide having an amino acid sequence with at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO:1 or SEQ ID NO:2; a gene localized to the Naga_100020g79 locus; and/or a gene that comprises an ORF comprising a sequence having at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO:3.

### Claim 56 (depends on 1)

A method for producing a mutant microorganism of claim 1, comprising introducing into said microorganism one or more mutations and/or one or more agents that attenuates the expression of a polypeptide comprising a GAF domain.

### Claim 57 (depends on 56)

The method of claim 56, wherein the one or more mutations affects the expression of a polypeptide comprising the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2; a gene localized to the Naga_100020g79 locus; or a gene comprising an open reading frame that comprises the nucleotide sequence of SEQ ID NO:3.

### Claim 58 (depends on 57)

The method of claim 57, wherein the one or more agents is selected from the group consisting of antisense RNA, RNAi, shRNA, microRNA, ribozyme, a meganuclease, a zinc finger nuclease, a component of a Cas/CRISPR system, and/or a component of a Transcription Activator-Like Effector Nuclease (TALEN) system.
